<DOC>
	<DOCNO>NCT02987530</DOCNO>
	<brief_summary>The purpose study compare impact two combination two tablet daily : dolutegravir associate emtricitabine / tenofovir versus darunavir / cobicistat associate emtricitabine / tenofovir DNA HIV measure PBMC 48 week patient primary HIV-1 infection .</brief_summary>
	<brief_title>National Multicenter Trial Evaluating Two Treatments Patients With Primary Human Immunodeficiency Virus ( HIV-1 ) Infection</brief_title>
	<detailed_description>Phase III , randomize ( 1 : 1 ) , comparative , superiority , open-label , parallel assignment , national multicenter trial evaluate two treatment patient primary HIV-1 infection . Comparison two combination regard : - Viral reservoir W48 - Early inhibition viral replication , - Plasmatic cellular cumulative viremia W48 , - Immune reconstitution CD4 , CD8 level CD4 / CD8 ratio , - Activation parameter decrease , - Adherence treatment , - Treatments tolerance , - Adverse event , - Quality life ( self-administered questionnaire ) . Study pharmacokinetics / dynamic relationship decay plasma , cellular , rectal spermatic compartment ' viral load . 50 participant per group enrol 40 site France . Co- inclusion ANRS CO 06 PRIMO cohort offer</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Age ≥ 18 year screen visit . Patients primary HIV1 infection : Any result achieve previous 10 day screen take account . If Enzyme Linked ImmunoSorbent Assay ( ELISA ) test result dissociate signal antibody p24 antigen : Negative ELISA positive HIV1 RNA confirm second positive HIV1 RNA . Positive ELISA WBHIV1 [ 05 ] band ( ) confirm positive HIV1 RNA . If ELISA test result dissociate p24 antigen antibody signal : ELISA Ac / p24 positive HIV1 RNA confirm second positive HIV1 RNA . ELISA Ac / p24 + confirm positive HIV1 RNA . ELISA Ac + / p24 + WBHIV1 [ 05 ] band ( ) confirm positive HIV1 RNA . Written inform consent sign person investigator later day screen visit exam perform trial ( article L112211 Public Health Code ) . Affiliate beneficiary social security system ( Article L112111 Public Health Code ) ( State Medical Aid AME social security system ) . Patients follow selected center , accept additional constraint sign consent , participate virological , immunological pharmacological substudies . Patient agree participate trial 1 year accord define term . Treatment Truvada® ( PreExposure Prohylaxis Postexposure prophylaxis ) 4 week precede inclusion . Associated pathology urgent care need . Prothrombin Ratio &lt; 50 % . Creatinine clearance &lt; 70 mL / min ( Cockroft ) . aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , bilirubin ( total conjugate ) ≥ 10 time upper limit normal . Patient isolate HIV2 viral strain . Women childbearing potential without effective contraception method ( see appendix A6 ) . Pregnant breastfeed woman . Person legal guardianship deprive liberty judicial administrative decision . Patient participate another research evaluate treatment exclusion period ongoing screen visit . Planned absence could prevent optimal trial participation ( vacation abroad , move , imminent job change ... ) . Coadministration prohibit treatment ( see § 9.5 ) . History presence allergy study drug component ; Unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ) , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Subjects severe hepatic impairment ( Class C ) determine ChildPugh classification . Any symptoms laboratory value suggest systemic disorder ( renal , hepatic , cardiovascular , pulmonary ) medical condition could interfere interpretation trial result compromise health patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>primary infection</keyword>
</DOC>